Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2

NCT07426913 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT07426913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07426913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2
Lead sponsor
Virginia Commonwealth University
Phase
Not applicable
Overall status
Recruiting
Start date
May 20, 2026
Completion date
September 28, 2027
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anthracycline related cardiotoxicity in breast cancer, breast cancer, trastuzumab, virtual reality